Stephanie Turpin
Family · Cleveland, OHNPI 1760669758
Payments from drug & device makers
Across 136 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$473
- AstraZeneca$313
- Lilly USA, LLC$208
- GSK$207
- Sanofi-aventis U.S. LLC$196
- Novo Nordisk$164
- plus $767 from 13 others
What the payments were for
- Food & beverage$2,30899%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $473 |
| AstraZeneca | 19 | $313 |
| Lilly USA, LLC | 12 | $208 |
| GSK | 14 | $207 |
| Sanofi-aventis U.S. LLC | 13 | $196 |
| Novo Nordisk | 9 | $164 |
| Amgen | 8 | $131 |
| Boehringer Ingelheim | 7 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $90 |
| Bayer | 5 | $83 |
| Xeris Pharmaceuticals, Inc. | 4 | $74 |
| Pfizer | 4 | $63 |
| Gilead | 3 | $62 |
| Exact Sciences | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
How this compares
$2,328 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 41 | $39,317 |
| OzempicSemaglutide | 27 | $28,478 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $18,948 |
| JardianceEmpagliflozin | 17 | $17,174 |
| Gabapentin | 58 | $1,347 |
| Duloxetine Hcl | 24 | $1,017 |
| Atorvastatin Calcium | 85 | $976 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $708 |
| Celecoxib | 23 | $653 |
| Omeprazole | 28 | $644 |
| Amlodipine Besylate | 59 | $466 |
| Pregabalin | 20 | $423 |
| Metoprolol Succinate | 33 | $402 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 21 | $397 |
| Lisinopril | 52 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $313 | $39,31741 claims |
| Novo NordiskOzempic | $164 | $28,47827 claims |
| GSKTrelegy Ellipta | $207 | $18,94815 claims |
| Boehringer IngelheimJardiance | $119 | $17,17417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.
Other family in Cleveland
- Tina CorkwellCleveland$55K
- Sophia WoodsonCleveland$53K
- Shannon ShafferCleveland$22K
- Christina FerraroCleveland$18K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.